Liquidation: Kiniksa Pharmaceuticals International, plc

Form Type: DEFA14A

Filing Date: 2025-04-21

Corporate Action: Liquidation

Type: New

Accession Number: 000110465925036929

Filing Summary: Kiniksa Pharmaceuticals International, plc has filed a proxy statement ahead of its upcoming 2025 Annual General Meeting, scheduled for June 3, 2025, at which several proposals will be voted on. Notably, Proposal 13 seeks authorization for a transaction involving the company’s wholly-owned subsidiary, Kiniksa Pharmaceuticals, Ltd. (referred to as Kiniksa Bermuda), to redeem preference shares. This will be executed through the capitalization of the company's merger reserve account and a court-approved cancellation of a merger reserve bonus share, facilitating the liquidation of Kiniksa Bermuda. Other proposals include the election of Class I, II, and III Directors, the appointment of PricewaterhouseCoopers LLP as auditors, and shareholder advisory votes on remuneration policies. The document emphasizes the importance of shareholders voting and encourages access to proxy materials online to ensure informed decisions.

Form Type: PRE 14A

Filing Date: 2025-04-10

Corporate Action: Liquidation

Type: New

Accession Number: 000110465925033788

Filing Summary: Kiniksa Pharmaceuticals International, plc is convening its Annual Meeting of Shareholders on June 3, 2025, at Third Floor, 23 Old Bond Street, London, UK. The proxy statement outlines several proposals including the re-election of directors, appointment of auditors, and compensation approvals. A significant item includes a proposal for the liquidation of Kiniksa Pharmaceuticals, Ltd. through the redemption of preference shares by capitalizing the Company’s merger reserve account, creating distributable reserves to facilitate this process. Voting entitlement is restricted to shareholders recorded by April 8, 2025, and instructions for voting are reiterated for clarity.